Formulation design and characterization of osmotically controlled tablet of Ramipril

Bhabani Shankar Nayak, P. Ellaiah, Suprava Sethy, Monalisha Nayak, Subham Sourajit


Objective: Ramipril is a long-acting angiotensin-converting enzyme inhibitor. The study aimed to design, formulate and evaluate the oral osmotic drug delivery dosage form of an anti-hypertensive drug, ramipril.

Methods: The tablet was formulated using ramipril and different polymers like PVP- K30 and Ethyl cellulose. The microcrystalline cellulose (MCC - diluent), Potassium chloride, Mannitol (osmogen) and Magnesium stearate (lubricant) were used in all the formulations. All the tablets were manufactured by wet granulation method followed by film coating. Compatibility of the drug with excipients was determined by FT-IR spectral analysis. The granules were evaluated for bulk density, Carr’s index and Hausner’s ration to determine flow properties. The prepared compressed and coated tablets were evaluated for weight variation, thickness, hardness, friability, and drug content and in vitro drug release and release kinetic studies.

Results: The FT-IR study revealed that drug was compatible with excipients.  The flow properties of granules of most formulation were excellent. All osmotic tablet formulations had good tablet physiochemical properties as per Pharmacopeia. The drug content of all tablet batches was satisfactory. The in vitro drug release study revealed that the formulation F7 containing 100 mg of ethyl cellulose release 100% of drug in 24 h with zero order release kinetics.

Conclusions: Ramipril osmotic tablet could be used for safe management of hypertension with greater novelty.


Osmotic, Hypertension, Control release, ACE inhibitor

Full Text:



Millar-Craig MW, Bishop CN, Raftery EB. Circadian variation of blood pressure. Lancet. 1978;1:795–7.

Giuseppe M, Alberto F, Luisa G, Gianfranco P, Guido P, Giovanni B, et al. Blood pressure and heart rate variabilities in normotensive and hypertensive human beings. Circ Res. 1983;53:96–104.

Gareth B, Gregory YHL, Eoin OB. The pathophysiology of hypertension. Bio Med J. 2001;322:912–6.

Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217–23.

Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, et al. Recommendations for blood pressure measurement in humans and experimental animals. Part 1: blood pressure measurement in humans. Hypertension. 2005;45(1):142–61.

Lachman L, Liberman HA, kanig JL. The Theory and Practice of Industrial Pharmacy. Philadelphia: Lea and Fibiger; 1989.

Aulton ME. Pharmaceutics, The Science of Dosage Form Design. 2nd ed. Livingstone: Churchil; 2002: 199-206.

Biradar SS, Bhagvati ST, Kuppasad IJ. Fast Dissolving Drug Delivery System: A Brief Overview. Int J Pharmacol. 2006;4(2):25-9.

Jaysukh J, Hirani DA. Orally Disintegrating Tablets: A Review. Trop J Pharm Res. 2009;8(2):161-72.

Bhowmik D, Chiranjib B. Fast Dissolving Tablet: An Overview. J Chem Pharm Res. 2009;1(1):163 –77.

The United States Pharmacopoeia. USP/NF, 25/20. The U. S. Pharmacopoeial Convention, Rackville, MD. 2002:2008-2012.

Balasubramaniam J, Bindu K. Influence of Superdisintgrants on Drug Dissolution from Solid dosage Forms. Pharm Tech Excipient Suppl. 2009;1(2):4-14.

Bandari S, Rajendra R. Ordispersible tablets: An overview. Asian Pharm. 2009;1(3):21-5.

Krishnaiah YSR. Designing of fast dissolving tablets. Indian J Pharm Sci. 2005;2(3):45-54.

Yunxia B, Yovinobu Y, Hisakazu S. Rapidly Disintegrating tablets prepared by the wet compression method. Indian J Pharm Sci. 2007;5(1):112-8.

Camarco W, Dipan R, Druffner A. Selecting Superdisintegrants for ODT Formulation. Pharm Tech Suppl. 2006;1(2):28-37.

Zentner GM, Rork GS, Himmelsteine KJ. Osmotic flow through controlled porosity films: an approach to deliver water soluble compounds. J Control Rel. 1985;2:217-29.

Herbig SM, Cardinal JR, Korsmeyer KL, Smith KL. Asymmetric-membrane tablet coatings for osmotic drug delivery. J Control Rel. 1995;35:127-36.

Nagakura T, Ishihara K, Furukawa T, Masuda K, Tsuda T. Auto-regulated Osmotic pump for insulin therapy by sensing glucose concentration without energy supply. Sensors Actuators. 1996;34:229-33.

Verma RK, Krishna DM, Garg S. Formulation aspects in the development of osmotically controlled oral drug delivery systems. J Control Rel. 2002; 79:7–27.

Mishra B, Makesh BK, Sankar C. Oral push-pull osmotic pumps of pentazocine hydrochloride: development and evaluation. Ind J Pharm Sci. 2006;68(1):85-7.

Ravi PR, Ganga S, Saha RN. Design and Study of Lamivudine Oral Controlled Release Tablets. AAPS PharmSciTech. 2007;8(4):101-13.

Kanagale P, Lohray BB, Misra A, Davadra P, Kini R. Formulation and optimization of porus osmotic pump-based Controlled Release System of Oxybutynin. AAPS PharmSciTech. 2007;8(4):53-8.

Philip AK, Pathak K. In situ formed phase transited drug delivery system of ketoprofen for achieving osmotic controlled and level a in vitro in vivo correlation. Ind J Pharm Sci. 2008;70(6):745-53.

Jones D. Pharmaceutical Statistics. London: Pharmaceutical Press; 2002.315-333.

Bolton S. Analysis of variance. In Pharmaceutical Statistics Practical and Clinical Application. New York: Marcel Dekker Inc.; 1997: 133-139.

Silverstein RM, Webster FX. Infrared Spectroscopy. In Spectrometric Identification of Organic Compound. 6th ed. New Delhi: Wiley India (P) Ltd.; 2005.71-100.

Kemp W. Infrared Spectroscopy. In Organic Spectroscopy. 3rd ed. New York: Palgrave Houndmills; 2009:19-65.



  • There are currently no refbacks.

Copyright (c) 2017 Pharmaceutical and Biological Evaluations

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Creative Commons License


© Copyright 2018 - Pharmaceutical and Biological Evaluations